Table 1.
Clinical, epidemiological and molecular data for MRSA isolates
| Characteristic | Genotype of the MRSA isolates | Total (N = 535) n (%) | HA- vs. CA-MRSA P value | ||
|---|---|---|---|---|---|
| HA-MRSA (N = 474), n (%) | CA-MRSA (N = 59), n (%) | Unique genotypes (N = 2), n (%) | |||
| Sex | 0·41 | ||||
| Male | 291 (61·4) | 39 (66·1) | 1 (50) | 331 (61·9) | |
| Female | 183 (38·6) | 20 (33·9) | 1 (50) | 204 (38·1) | |
| Demographic data (age in years) | |||||
| ⩽19 | 2 (0·4) | 0 | 0 | 2 (0·4) | 0·62 |
| 20–29 | 5 (1·1) | 6 (10·2) | 1 (50) | 12 (2·2) | <0·0001 |
| 30–39 | 6 (1·2) | 16 (27·1) | 0 | 22 (4·1) | <0·0001 |
| 40–49 | 23 (4·9) | 6 (10·2) | 0 | 29 (5·4) | 0·09 |
| 50–59 | 54 (11·4) | 6 (10·2) | 1 (50) | 61 (11·4) | 0·78 |
| 60–69 | 91 (19·2) | 10 (16·9) | 0 | 101 (18·9) | 0·68 |
| 70–79 | 137 (28·9) | 6 (10·2) | 0 | 143 (26·7) | 0·002 |
| 80–89 | 129 (27·2) | 5 (8·4) | 0 | 134 (25·1) | 0·002 |
| ⩾90 | 27 (5·7) | 4 (6·8) | 0 | 31 (5·8) | 0·74 |
| Primary infection sites | |||||
| Central intravenous catheters | 95 (20) | 3 (5·1) | 1 (50) | 99 (18·5) | 0·005 |
| Pulmonary infection | 65 (13·7) | 12 (20·3) | 0 | 77 (14·4) | 0·17 |
| Skin/soft tissue infection | 64 (13·5) | 16 (27·2) | 1 (50) | 81 (15·1) | 0·006 |
| Surgical site infection | 50 (10·6) | 6 (10·2) | 0 | 56 (10·5) | 0·93 |
| Urinary tract infection | 58 (12·2) | 4 (6·8) | 0 | 62 (11·6) | 0·22 |
| Bone and joint infection | 45 (9·5) | 5 (8·4) | 0 | 50 (9·3) | 0·80 |
| Other | 38 (8) | 3 (5·1) | 0 | 41 (7·7) | 0·43 |
| Unknown | 59 (12·5) | 10 (16·9) | 0 | 69 (12·9) | 0·33 |
| Origin of infection | |||||
| Healthcare origin | 361 (73·2) | 13 (22) | 2 (100) | 376 (70·3) | <0·0001 |
| Community origin | 104 (21·9) | 45 (76·3) | 149 (27·8) | <0·0001 | |
| Unknown origin | 9 (1·9) | 1 (1·7) | 0 | 10 (1·9) | 0·91 |
| Community-associated risk factors | <0·0001 | ||||
| Injection drug users | 1 (0·2) | 17 (28·8) | 0 | 18 (3·4) | |
| Inmate | 0 | 3 (5·1) | 0 | 3 (0·6) | |
| PVL toxin gene | <0·0001 | ||||
| Negative | 474 (100) | 6 (10·2) | 1 (50) | 481 (89·9) | |
| Positive | 0 | 53 (89·8) | 1 (50) | 54 (11·1) | |
MRSA, Methicillin-resistant Staphylococcus aureus; HA, healthcare associated; CA, community acquired.